|Bid||259.83 x 900|
|Ask||260.59 x 800|
|Day's Range||255.79 - 261.06|
|52 Week Range||126.50 - 273.25|
|PE Ratio (TTM)||52.58|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||255.67|
Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.
Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), with a market cap of US$5.58b, often getRead More...
Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.
Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry. However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense. Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume. SEE ALSO: The 25 Best Stocks to Buy (According to Hedge Funds)
Progenics Pharmaceuticals' (PGNX) shares down on disappointing results from phase III study evaluating imaging agent, 1404, for prostate cancer detection.
Zacks.com highlights: Attunity, Helix Energy Solutions Group, Ligand Pharmaceuticals, Turtle Beach and SVB Financial Group
The stock market was modestly higher amid an exchange of tariffs between the U.S. and China. FedEx fell after its EPS report.
Founder stories are much more interesting than product specs, and this profile is legitimately interesting, but what does it matter that we understand Zuck when Zuck himself so clearly doesn’t even understand Facebook. “Zuck himself so clearly doesn’t even understand Facebook” strikes me as a completely fair and not even controversial position. Mark Zuckerberg built an online facebook for Harvard students.
The Securities and Exchange Commission charged Gregory Lemelson and Massachusetts-based Lemelson Capital Management LLC with fraud for allegedly illegally profiting from a scheme to drive down the price of San Diego-based Ligand Pharmaceuticals Inc., by taking a short position on behalf of The Amvona Fund, a hedge fund he advised and partly owned and then issuing false information about Ligand. The SEC alleges Lemelson used written reports, interviews, and social media to spread untrue claims, including that Ligand was "teetering on the brink of bankruptcy" and that Ligand's investor relations firm agreed with his view that its flagship Hepatitis C drug, Promacta, was going to become obsolete. Lemelson also allegedly misled investors by citing a European doctor's negative views on the same Ligand drug without revealing the doctor was Amvona's largest investor and had a significant financial interest in seeing Ligand's stock price decline. According to the SEC's complaint, Ligand's stock lost more than one-third of its value during the course of Lemelson's alleged scheme. Short-sellers profit when the price of stock declines. Lemelson collected more than $1.3 million in trading profits for the adviser and the hedge fund. The complaint names the Amvona Fund as a relief defendant and seeks to have it return gains it obtained as a result of Lemelson and his firm's alleged misconduct.
MARLBOROUGH, Mass. , Sept. 12, 2018 /PRNewswire/ -- Rev. Fr. Emmanuel Lemelson , the Chief Investment Officer of Lemelson Capital Management, today responded to a civil complaint filed by the United States ...
177Lu-PSMA-617, a prostate specific membrane antigen-targeted radioligand therapy, is Endocyte's (ECYT) lead program. It is being evaluated in a phase III study for mCRPC for PSMA-positive patients
Does Ligand Pharmaceuticals (LGND) have what it takes to be a top stock pick for momentum investors? Let's find out.
The best biotech companies to invest in tend to have a commonality: A strong streak of earnings growth.
bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.
Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.
Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.